Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

 Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19

Shots:

  • Shionogi to receive an up front, milestones as well as royalties on sales of the therapy. BioAge to get exclusive US and EU rights to develop and commercialize BGE-17 for COVID-19
  • Additionally, BioAge gets an exclusive right to negotiate a license for additional indications and plans to initiate P-II study of BGE-175 for COVID-19 in the H1’21
  • BGE-175 is a DP1 receptor antagonist, developed for allergic rhinitis. The results of multiple non-clinical/ clinical trials in 2,400+ subjects & have shown that BGE-175 has high affinity and selectivity to the DP1 receptor1 & is well tolerated & safe

Click here ­to­ read full press release/ article | Ref: Shionogi | Image: BusinessWire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post